EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Effect of Rituximab on Neurofilament Levels in CIDP : Results From the CIDPRIT Randomized Trial

Pietro Emiliano Doneddu iD, Roger Collet-Vidiella iD, Chiara Gallo, Dario Cocito, Fiore Manganelli iD, Yuri Falzone, Eleonora Dalla Bella, Luana Benedetti, Anna Mazzeo, Erdita Peci, Emanuele Spina iD, Camilla Strano und 7 weitere

Journal of the Peripheral Nervous System · 2026

DOI: 10.1111/jns.70107 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of the Peripheral Nervous System, 2026. Verfasst von Pietro Emiliano Doneddu und 18 weiteren Autor:innen. Beteiligte Einrichtung: Neuromuscular and Neuroimmunology Unit, IRCCS Humanitas Research Hospital, Milan, Italy. Hauptthemen laut MEDLINE: Rituximab, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, Neurofilament Proteins, Immunologic Factors. Die Arbeit nennt 28 Literaturangaben. Gefördert von: Agenzia Italiana del Farmaco, Ministero della Salute, GBS/CIDP Foundation International (USA).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims Rituximab has been proposed as a potential treatment in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), but formal evidence regarding its clinical effectiveness is weak. The CIDPRIT trial found no clinical benefit in comparison with placebo, but secondary analyses suggested some beneficial effect. Analysis of serum neurofilament light chain (sNfL) may provide evidence to support rituximab's effect on CIDP patients.

Methods

We performed a post hoc analysis of sNfL levels from the CIDPRIT trial participants. Blood samples were collected at baseline, month 6, and 12. sNfL was measured using Simoa technology. Geometric means and z‐scores were compared across groups. Linear mixed‐effects models and survival analyses were used to evaluate treatment effects and clinical correlations.

Results

33 participants were included (18 rituximab, 15 placebo). Baseline sNfL was significantly higher in the rituximab group (11.51 vs. 6.67 pg/mL, p = 0.019). While between‐group differences over time were not statistically significant, rituximab‐treated patients showed stable sNfL levels at month 6 and a slight decrease at month 12, contrasting with modest increases in the placebo group. Among rituximab‐treated patients who remained clinically stable at month 12, sNfL showed a non‐significant decline by 31%. No significant associations were found between baseline sNfL and clinical worsening. NfL levels correlated with neurophysiological parameters of axonal damage.

Interpretation

The analysis did not demonstrate biomarker‐based evidence of rituximab efficacy in CIDP. However, observed trends suggest a possible biological effect in reducing axonal injury in a subset of patients. Further studies are needed to clarify the role of sNfL in treatment monitoring and patient stratification.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RituximabPolyradiculoneuropathy, Chronic Inflammatory DemyelinatingNeurofilament ProteinsImmunologic FactorsHumansFemaleMaleMiddle AgedAgedAdultBiomarkers

Stichwörter der Autor:innen

CIDPbiomarkerschronic inflammatory demyelinating polyradiculoneuropathyneurofilamentsrituximab

Substanzen

RituximabNeurofilament ProteinsImmunologic Factorsneurofilament protein LBiomarkers

Autor:innen und Institutionen

  • Neuromuscular and Neuroimmunology Unit, IRCCS Humanitas Research Hospital, Milan, Italy.
  • Department of Biomedical Sciences, Humanitas University, Milan, Italy.
  • Neuromuscular Diseases Unit, Department of Neurology, Barcelona, Spain.
  • Department of Clinical and Biological Sciences, University of Turin, Torino, Italy.
  • Department of Neuroscience, Reproductive Sciences and Odontostomatology, University of Naples 'Federico II', Napoli, Italy.
  • Division of Neuroscience, Department of Neurology, Institute of Experimental Neurology (INSPE), san Raffaele Scientific Institute, Milano, Italy.

ORCID-Profile: Pietro Emiliano Doneddu, Roger Collet-Vidiella, Fiore Manganelli, Emanuele Spina, Giuseppe Liberatore, Elisa Bianchi, Luis Querol, Eduardo Nobile-Orazio

Förderung

  • Agenzia Italiana del Farmaco, Ministero della Salute
  • GBS/CIDP Foundation International (USA)

Zitieren

APA

Doneddu, P. E., Collet-Vidiella, R., Gallo, C., Cocito, D., Manganelli, F., Falzone, Y., Bella, E. D., Benedetti, L., Mazzeo, A., Peci, E., Spina, E., Strano, C., Germano, F., Gentile, L., Liberatore, G., Cutellè, C., Bianchi, E., Querol, L., & Nobile-Orazio, E. (2026). Effect of Rituximab on Neurofilament Levels in CIDP : Results From the CIDPRIT Randomized Trial. Journal of the Peripheral Nervous System. https://doi.org/10.1111/jns.70107

Vancouver

Doneddu PE, Collet-Vidiella R, Gallo C, Cocito D, Manganelli F, Falzone Y, et al. Effect of Rituximab on Neurofilament Levels in CIDP : Results From the CIDPRIT Randomized Trial. Journal of the Peripheral Nervous System. 2026. doi:10.1111/jns.70107

BibTeX
@article{Doneddu2026,
  author = {Doneddu, Pietro Emiliano and Collet-Vidiella, Roger and Gallo, Chiara and Cocito, Dario and Manganelli, Fiore and Falzone, Yuri and Bella, Eleonora Dalla and Benedetti, Luana and Mazzeo, Anna and Peci, Erdita and Spina, Emanuele and Strano, Camilla and Germano, Francesco and Gentile, Luca and Liberatore, Giuseppe and Cutellè, Claudia and Bianchi, Elisa and Querol, Luis and Nobile-Orazio, Eduardo},
  title = {Effect of Rituximab on Neurofilament Levels in CIDP : Results From the CIDPRIT Randomized Trial},
  journal = {Journal of the Peripheral Nervous System},
  year = {2026},
  doi = {10.1111/jns.70107}
}
Kostenlos starten →